Medical Care Costs Associated with Postmenopausal Estrogen Plus Progestogen Therapy
نویسندگان
چکیده
منابع مشابه
Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy.
Working Group Members1 Garnet L. Anderson, Women’s Health Initiative, Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M3-A410, PO Box 19024, Seattle, WA 98109, USA Philippe Autier, Unit of Epidemiology, Prevention and Screening, Jules Bordet Institute, Boulevard de Waterloo 125, Brussels 1000, Belgium Valerie Beral, Cancer Epidemiology Unit, Univers...
متن کاملCombined Estrogen–progestogen Contraceptives
Combined hormonal contraceptives consist of an estrogen and a progestogen, and act primarily by preventing ovulation through the inhibition of the follicle-stimulating hormone and luteinizing hormone. The progestogen component also renders the cervical mucus relatively impenetrable to sperm, and reduces the receptivity of the endometrium to implantation (IARC, 2007). A variety of innovations ha...
متن کاملCombined Estrogen–progestogen Contraceptives
Combined hormonal contraceptives consist of an estrogen and a progestogen, and act primarily by preventing ovulation through the inhibition of follicle-stimulating hormone and luteinizing hormone. The progestogen component also renders the cervical mucus relatively impenetrable to sperm and reduces the receptivity of the endometrium to implantation. These mechanisms render combined hormonal con...
متن کاملCombined Estrogen–progestogen Contraceptives
Combined hormonal contraceptives consist of an estrogen and a progestogen, and act primarily by preventing ovulation through the inhibition of the follicle-stimulating hormone and luteinizing hormone. The progestogen component also renders the cervical mucus relatively impenetrable to sperm, and reduces the receptivity of the endometrium to implantation (IARC, 2007). A variety of innovations ha...
متن کاملModeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy.
OBJECTIVE To estimate the annual cost and outcome impacts attributable to raloxifene, alendronate, and estrogen-progestin therapy as prevention therapies among postmenopausal women over the first 7 years of hormone replacement therapy (HRT). METHODS A budget-impact model was devised to compare the costs, benefits, and costs per event avoided for various postmenopausal therapies (raloxifene, a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2004
ISSN: 1098-3015
DOI: 10.1111/j.1524-4733.2004.75006.x